BioCryst Pharmaceuticals Inc (BCRX) company profile
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
About BioCryst Pharmaceuticals
Biological Products, (No Diagnostic Substances), SIC 2836
BioCryst Pharmaceuticals discovers, develops, and commercializes therapies targeting rare diseases and acute medical conditions. The company's lead commercial product, ORLADEYO, is an oral, once-daily therapy approved for the prevention of hereditary angioedema attacks in adult and pediatric patients. Its commercial portfolio also includes RAPIVAB, an intravenous neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza. Additionally, the company advances a clinical pipeline of small-molecule and protein drug candidates for indications such as Netherton syndrome, diabetic macular edema, and atopic dermatitis. BioCryst distributes its therapies to patients through specialty pharmacy providers and collaborates with government bodies, commercial licensees, and healthcare distributors to supply medicines to global healthcare systems.
BioCryst maintains commercial teams and partnerships across international markets, including the United States, Japan, Australia, Canada, Korea, and Latin America. Its European ORLADEYO business was transferred to a regional commercial partner. The provided text does not state the location of the company's headquarters.
Summary of the business section of BioCryst Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioCryst Pharmaceuticals Inc
- Founded
- 1986
- Headquarters
- Durham, NC
- Address
- 4505 Emperor Boulevard, Suite 200 27703
- Phone
- (919) 859-1302
- Website
- www.biocryst.com
- Employees
- 435, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- BCRX
- Exchange
- Nasdaq
- IPO date
- Sep 26, 1996
- Shares outstanding
- 256M, Jul 31, 2026
- Public float
- $1.86B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 882796
- CUSIP
- 09058V103
- ISIN
- US09058V1035
- FIGI
- BBG000BLYWX6
- Share class FIGI
- BBG001S7K151
- LEI
- 549300Z0INP1Z5NP6J59
- EIN
- 62-1413174
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alane P. Barnes | Chief Legal Officer | 463,203 |
| Sandeep Menon | Chief R&D Officer | 205,150 |
| Ronald Dullinger | Chief Commercial Officer | 258,372 |
| Charles K. Gayer | President and CCO | 902,583 |
| Babar Ghias | Chief Financial Officer | 268,700 |
| Helen M. Thackray | Chief R&D Officer | 377,318 |
| Anthony Doyle | Chief Financial Officer | 377,867 |
| Amy E. McKee | Director | 47,821 |
| Jon P. Stonehouse | Director | 1,420,419 |
| Jill C. Milne | Director | 33,226 |
| Vincent Milano | Director | 109,642 |
| Steven Frank | Director | 36,747 |
| Machelle Sanders | Director | 45,936 |
| Alan G. Levin | Director | 79,565 |
| Steven K. Galson | Director | 86,165 |
| Theresa Heggie | Director | 80,646 |
| Nancy J. Hutson | Director | 99,138 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $12.95M | $1.16M | $5.69M | $105 | $201 |
| FY2024 | $8.32M | $10.98M | $3.37M | $101 | $156 |
| FY2023 | $4.78M | -$3.69M | $1.96M | $80 | $144 |
| FY2022 | $6.98M | $4.01M | $2.57M | $154 | $139 |
| FY2021 | $7.06M | $17.05M | $4.52M | $186 | $124 |
| FY2020 | $6.03M | $10.85M | $2.35M | $216 | $111 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Jon P. Stonehouse Former President and Chief Executive Officer | $728.47K | – | – | $11.13M | $1.05M | $37.53K | $12.95M | +56% |
| Anthony J. Doyle Former Chief Financial Officer and Treasurer | $151.93K | – | $708.69K | $1.17M | – | $114.70K | $2.14M | -35% |
| Babar Ghias Chief Financial Officer | $271.52K | $160.00K | $2.12M | $3.68M | $506.40K | $10.50K | $6.75M | – |
| Helen M. Thackray, M.D. Former Chief R&D Officer | $426.00K | – | $1.17M | $1.26M | $756.11K | $733.26K | $4.34M | +22% |
| Alane P. Barnes Chief Legal Officer and Corporate Secretary | $542.52K | – | $867.72K | $3.63M | $553.37K | $17.50K | $5.62M | +73% |
| Charles K. Gayer President and Chief Executive Officer; Former Chief Commercial Officer | $609.40K | – | $3.36M | $4.89M | $749.09K | $17.50K | $9.63M | +185% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 435 employees, of whom approximately 118 employees were engaged in the research and development function of our operations, which we define to include any employee included in research and development expenses for financial reporting purposes.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 23, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 20, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 30, 2018 | Merger vote | Definitive merger proxy statement |
| Mar 29, 2018 | Merger vote | Definitive merger proxy statement |
| Sep 26, 1996 | IPO | Initial public offering priced (424B4 prospectus) |
See a number that looks wrong?